10038-81-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-[(phenylsulfonyl)amino]benzoate is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 2-[(phenylsulfonyl)amino]benzoate serves as an intermediate for the production of agrochemicals, aiding in the creation of compounds that protect crops and enhance agricultural productivity.
Used in Organic Chemistry:
Methyl 2-[(phenylsulfonyl)amino]benzoate is employed as a building block in organic chemistry, acting as a starting material for the preparation of more complex compounds, thus expanding the scope of chemical research and development.

Upstream product

• 34837-67-7 2-(phenylsulfonamido)benzoic acid 
• 98-09-9 benzenesulfonyl chloride 
• 118-92-3 anthranilic acid 
• 134-20-3 2-carbomethoxyaniline 
• 67-56-1 methanol 
• 94475-22-6 N-benzenesulfonyl-anthraniloyl chloride 

Downstream Products

• 34837-67-7 2-(phenylsulfonamido)benzoic acid 
• 52910-90-4 N-benzenesulfonyl-anthranilic acid amide 
• 824975-51-1 methyl 4-({2-[(phenylsulfonyl)amino]benzoyl}amino)benzoate 
• 312-63-0 N-(4-fluorophenyl)benzenesulfonamide 
• 1678-25-7 N-phenylbenzenesulfonamide 
• 152342-36-4 2-(N-Mesyl-2-methoxycarbonylanilino)-5-methoxy-1,4-benzoquinone 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having benzoic acid structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME

The present invention relates to a novel class of compounds comprising formula I, wherein n is 0 or 1. A is NR1, O, or S, wherein R1 is H, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, alkenyl, aryl, alkylaryl or arylalkyl. X is a carboxylate, a phosphonate, or a phosphate residue, or a C1-C10 alkyl residue optionally substituted with a carboxylate, phosphonate or phosphate residue. Y is a C1-C20 alkyl, alkenyl, halide, hydroxyl, C1-C20 alkoxy, aryl, alkylaryl, arylalkyl, cycloalkyl, cycloalkenyl, or a heterocyclic ring and is optionally substituted with one or more halides. Z is a H, a hydroxyl group, a halide, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, a cycloalkenyl group or a heterocyclic ring and is optionally substituted with one or more C1-C10 alkyl groups, C1-C10alkoxy groups, hydroxyl groups, cyano groups, carboxylate groups, halides, aryl groups, alkylaryl groups, arylalkyl groups, cycloalkyl groups, cycloalkenyl groups or heterocyclic rings.

Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors

The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.

Discovery of new chemical leads for selective EP1 receptor antagonists

A series of 4-({2-[alkyl(phenylsulfonyl)amino]phenoxy}methyl)benzoic acids were identified as functional PGE2 antagonists with selectivity for the EP1 receptor subtype starting from a chemical lead 1, which was found while screening our in-house compound library. Discovery of the optimized analogs 21-23 is presented here and structure-activity relationships (SAR) are also discussed.